Finorify

BSX

Boston Scientific Corp.

$43.34-4.14%

Price

BSX daily closing price
Market cap
$63.72 billion
P/E (TTM)
17.55
EV/EBITDA
13.31
52W range
$42.63 – $108.14
Volume
22.7M
Sector
Healthcare

Boston Scientific Corp. (BSX) last closed at $43.34, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for BSX, covered for search and blurred for visitors.

Performance

  • 1D-2.35%
  • 5D+3.51%
  • 1M-0.91%
  • 3M+2.13%
  • 6M-31.39%
  • 1Y-55.72%
  • 5Y+6.51%

Financials

BSX revenueQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Over the latest four reported periods ending June 30, 2026, Boston Scientific Corp. reported revenue of $21 billion.

The prior window totaled $18.5 billion, so the latest window is higher than that stretch.

Operating cash flow in the latest window was $4.53 billion.

Free cash flow in the latest window was $3.63 billion.

These amounts are taken from Boston Scientific Corp.'s SEC filings and are a snapshot as of June 30, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.

A few ratios from those statements: Profitability: ROE 3.6% (27 of 100). Leverage: D/E 0.44× (82 of 100). Cash generation: FCF margin 17.3% (35 of 100). Net margin: 16.6% (42 of 100). Liquidity: Current 1.24× (62 of 100).

Finorify's notes from those filings, written September 14, 2026: Category-Leading Proprietary MedTech Portfolio. Boston Scientific holds dominant market positions in specialized, high-growth interventional markets such as electrophysiology (e.g., FARAPULSE pulsed field ablation), structural heart (e.g., WATCHMAN left atrial appendage closure), and endoscopy. These clinically differentiated, IP-protected technologies command premium pricing and create high clinical switching costs for physicians trained on specific device interfaces. Deep Institutional and Clinical Integration. The company benefits from expansive global sales infrastructure and long-standing relationships with hospital systems, catheterization labs, and specialized surgeons. The steep learning curve and extensive clinical training required to operate complex interventional hardware entrench Boston Scientific's products within hospital workflows, generating sticky recurring revenue from single-use devices and consumables. Proven R&D Engine and Strategic M&A Integration. Boston Scientific consistently regenerates its growth profile through a disciplined model of venture investments, strategic tuck-in acquisitions, and internal R&D. By efficiently shepherding novel clinical technologies through complex multi-geography regulatory approval and reimbursement pathways, the company systematically enters fast-growing therapeutic adjacencies ahead of broad market commoditization. Rapid Innovation Cycles and Threat of Technological Obsolescence. The medical device industry is characterized by aggressive competitive R&D from well-capitalized peers. Disruptive clinical data, alternative therapeutic modalities (such as pharmaceutical advancements or next-generation ablation systems), or rival device launches can rapidly erode market share in key revenue-driving categories. Rigorous Regulatory Scrutiny and Product Liability Exposure. Class III medical devices face stringent pre-market approval and post-market surveillance globally, including complex compliance under EU Medical Device Regulation (MDR) and the US FDA. Product recalls, manufacturing quality issues, or adverse clinical outcomes can lead to major regulatory sanctions, remediation costs, brand impairment, and substantial product liability litigation. Healthcare Cost Containment and Reimbursement Headwinds. Boston Scientific's commercial success depends on favorable reimbursement coverage from government programs (like Medicare/Medicaid) and private third-party payers. Centralized hospital procurement, value-based care initiatives, and international price-control mechanisms (such as volume-based procurement in China) exert ongoing downward pressure on procedure volumes and device pricing.

Cash Flow

BSX free cash flowQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Margins

BSX operating margin

Valuation

P/E (TTM)
17.55
P/S (TTM)
3.03
EV/EBITDA
13.31

Insights

Advantage

Category-Leading Proprietary MedTech Portfolio

Boston Scientific holds dominant market positions in specialized, high-growth interventional markets such as electrophysiology (e.g., FARAPULSE pulsed field ablation), structural heart (e.g., WATCHMAN left atrial appendage closure), and endoscopy. These clinically differentiated, IP-protected technologies command premium pricing and create high clinical switching costs for physicians trained on specific device interfaces.

Advantage

Deep Institutional and Clinical Integration

The company benefits from expansive global sales infrastructure and long-standing relationships with hospital systems, catheterization labs, and specialized surgeons. The steep learning curve and extensive clinical training required to operate complex interventional hardware entrench Boston Scientific's products within hospital workflows, generating sticky recurring revenue from single-use devices and consumables.

Advantage

Proven R&D Engine and Strategic M&A Integration

Boston Scientific consistently regenerates its growth profile through a disciplined model of venture investments, strategic tuck-in acquisitions, and internal R&D. By efficiently shepherding novel clinical technologies through complex multi-geography regulatory approval and reimbursement pathways, the company systematically enters fast-growing therapeutic adjacencies ahead of broad market commoditization.

Risk

Rapid Innovation Cycles and Threat of Technological Obsolescence

The medical device industry is characterized by aggressive competitive R&D from well-capitalized peers. Disruptive clinical data, alternative therapeutic modalities (such as pharmaceutical advancements or next-generation ablation systems), or rival device launches can rapidly erode market share in key revenue-driving categories.

Risk

Rigorous Regulatory Scrutiny and Product Liability Exposure

Class III medical devices face stringent pre-market approval and post-market surveillance globally, including complex compliance under EU Medical Device Regulation (MDR) and the US FDA. Product recalls, manufacturing quality issues, or adverse clinical outcomes can lead to major regulatory sanctions, remediation costs, brand impairment, and substantial product liability litigation.

Risk

Healthcare Cost Containment and Reimbursement Headwinds

Boston Scientific's commercial success depends on favorable reimbursement coverage from government programs (like Medicare/Medicaid) and private third-party payers. Centralized hospital procurement, value-based care initiatives, and international price-control mechanisms (such as volume-based procurement in China) exert ongoing downward pressure on procedure volumes and device pricing.

Read the live analysis in Finorify

Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.

Open BSX in Finorify